Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pipeline Potential | Explore Pfizer's strategic focus on oncology and weight management, with promising developments in SSGJ-707 for non-small cell lung cancer treatment |
Financial Health | Discover Pfizer's robust financials, including a 74% gross profit margin and 6.8% dividend yield, with maintained revenue guidance of $61-64 billion for FY2025 |
Market Positioning | Analysts view Pfizer as undervalued compared to peers, with price targets ranging from $24 to $36, reflecting potential for growth and margin expansion |
Strategic Challenges | Learn about Pfizer's response to setbacks in clinical trials and its ambitious cost optimization strategy, aiming for $4.5 billion in net savings by 2025 |
Metrics to compare | PFE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPFEPeersSector | |
|---|---|---|---|---|
P/E Ratio | 20.3x | 21.5x | −0.6x | |
PEG Ratio | −5.90 | 0.43 | 0.00 | |
Price/Book | 1.7x | 1.8x | 2.6x | |
Price / LTM Sales | 2.5x | 2.4x | 3.3x | |
Upside (Analyst Target) | −2.3% | 0.0% | 44.8% | |
Fair Value Upside | Unlock | 23.7% | 5.5% | Unlock |